Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Search Results

1,407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune Checkpoint Therapies in Prostate Cancer.
Goswami S, Aparicio A, Subudhi SK. Goswami S, et al. Cancer J. 2016 Mar-Apr;22(2):117-20. doi: 10.1097/PPO.0000000000000176. Cancer J. 2016. PMID: 27111907 Free PMC article. Review.
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.
Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Goswami S, et al. J Clin Invest. 2018 Aug 31;128(9):3813-3818. doi: 10.1172/JCI99760. Epub 2018 Jul 30. J Clin Invest. 2018. PMID: 29905573 Free PMC article.
Frontiers in cancer immunotherapy-a symposium report.
Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R, Sosman JA, Cemerski S, Zavitsanou AM, Proia T, Egeblad M, Nolan G, Goswami S, Spranger S, Mackall CL. Cable J, et al. Among authors: goswami s. Ann N Y Acad Sci. 2021 Apr;1489(1):30-47. doi: 10.1111/nyas.14526. Epub 2020 Nov 13. Ann N Y Acad Sci. 2021. PMID: 33184911 Review.
Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.
Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Chahoud J, et al. Among authors: goswami s. Urol Oncol. 2021 Feb;39(2):134.e9-134.e16. doi: 10.1016/j.urolonc.2020.10.019. Epub 2020 Nov 10. Urol Oncol. 2021. PMID: 33187886
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Alhalabi O, et al. Among authors: goswami s. Int J Cancer. 2021 Jul 15;149(2):387-393. doi: 10.1002/ijc.33560. Epub 2021 Mar 24. Int J Cancer. 2021. PMID: 33739450
The Next Decade of Immune Checkpoint Therapy.
Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. Sharma P, et al. Among authors: goswami s. Cancer Discov. 2021 Apr;11(4):838-857. doi: 10.1158/2159-8290.CD-20-1680. Cancer Discov. 2021. PMID: 33811120 Review.
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Siddiqui BA, et al. Among authors: goswami s. J Immunother Cancer. 2021 Jul;9(7):e002850. doi: 10.1136/jitc-2021-002850. J Immunother Cancer. 2021. PMID: 34326169 Free PMC article.
1,407 results